Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Similar documents
Steviol Glycosides from Stevia rebaudiana Bertoni

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

Quetiapine Tablets. Expert Committee Monographs Chemical Medicines 4 Reason for Revision Compliance

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

1 out of 8. Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 86th Meeting 2018 ERYTHROSINE

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

This revision also necessitates a change in the table numbering in the test for Organic Impurities.

Continuation of Reversed-Phase HPLC Analysis Studies of Steviol Glycosides Isolated From Stevia rebaudiana Bertoni

Tramadol Hydrochloride Extended-Release Tablets. Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance

Tenofovir disoproxil fumarate (Tenofoviri disoproxili fumaras)

ISOMALT. Chemical formula 6-O-alpha-D-Glucopyranosyl-D-sorbitol: C 12 H 24 O 11 1-O-alpha-D-Glucopyranosyl-D-mannitol dihydrate: C 12 H 24 O 11 2H 2 O

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016.

Lutein Esters from Tagetes Erecta

Jagua (Genipin-Glycine) Blue (Tentative)

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

contents of the monograph in effect today. Please refer to the current edition of the USP NF for official text.

ASSAY AND IMPURITY METHOD FOR DURACOR TABLETS BY HPLC

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Revision Bulletin 28 Jul Aug 2017 Chemical Medicines Monographs 3

ABACAVIR SULFATE Proposal for revision of The International Pharmacopoeia (August 2012)

Telmisartan and Hydrochlorothiazide Tablets. Type of Posting. Revision Bulletin Posting Date. 26 Jan 2018 Official Date

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

ARTENIMOLUM ARTENIMOL. Adopted revised text for addition to The International Pharmacopoeia

PAPRIKA EXTRACT SYNONYMS DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

Compliance. Should you have any questions, please contact Behnaz Almasi, Associate Scientific Liaison ( or

SUCROSE OLIGOESTERS TYPE I

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

EMTRICITABINE AND TENOFOVIR TABLETS

Diltiazem Hydrochloride Extended-Release Capsules. Type of Posting Posting Date Official Date

CYCLOSERINE Proposal for revision of The International Pharmacopoeia (August 2012)

PROPOSAL FOR REVISION OF MONOGRAPH PUBLISHED IN The International Pharmacopoeia: REVISION OF ph test ABACAVIR ORAL SOLUTION (JULY 2012)

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

TENOFOVIRI DISOPROXILIS FUMARAS TENOFOVIR DISOPROXIL FUMARATE

Methotrexate. (Ph. Eur. monograph 0560) C 20 H 22 N 8 O Action and use. Dihydrofolate reductase inhibitor; cytostatic.

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

Title Revision n date

Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison ( or

β-carotene-rich Extract From Dunaliella Salina

Pelagia Research Library

IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page:

Sucrose Esters of Fatty Acids

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

Flupyradifurone. HPLC Method

Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method

RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form

Revision Bulletin 23 Feb Mar 2018 Chemical Medicines Monographs 3 Compliance

Aripiprazole (USP) We have followed the current Aripiprazole USP monograph (USP38-NF33):

CLINDAMYCIN PHOSPHATE (CLINDAMYCINI PHOSPHAS) REVISED DRAFT MONOGRAPH FOR INCLUSION IN The International Pharmacopoeia (August 2016)

J Pharm Sci Bioscientific Res (4): ISSN NO

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

USP purity analysis of pravastatin sodium using the Agilent 1120 Compact LC

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

Pharmacopeial Forum 818 INTERIM REVISION ANNOUNCEMENT Vol. 35(4) [July Aug. 2009] ERRATA

AMERICAN SPIKENARD FOR HOMOEOPATHIC PREPARATIONS ARALIA RACEMOSA FOR HOMOEOPATHIC PREPARATIONS

Pelagia Research Library

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Should you have any questions, please contact Heather Joyce, Ph.D., Senior Scientific Liaison ( or

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

SIMAROUBA CEDRON FOR HOMOEOPATHIC PREPARATIONS CEDRON FOR HOMOEOPATHIC PREPARATIONS

Airo International Research Journal ISSN : Volume : 7 October 2015

The International Pharmacopoeia TENOFOVIR DISOPROXIL FUMARATE (JULY 2012)

The Tacrolimus Capsules Revision Bulletin supersedes the currently official monograph.

Sanjog Ramdharane 1, Dr. Vinay Gaitonde 2

Analytical Method Development for USP Related Compounds in Paclitaxel Using an Agilent Poroshell 120 PFP

Yeast Extracts containing Mannoproteins (Tentative)

CLINDAMYCIN PALMITATE

Hydroxypropyl Starch (Tentative)

Change to read: BRIEFING

THERMALLY OXIDIZED SOYA BEAN OIL interacted with MONO- and DIGLYCERIDES of FATTY ACIDS

Journal of Pharmacreations

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION

A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

PROPOSAL FOR REVISION OF MONOGRAPH IN THE FOURTH EDITION OF The International Pharmacopoeia MEFLOQUINE HYDROCHLORIDE (JANUARY 2012) DRAFT FOR COMMENT

THERMALLY OXIDIZED SOYA BEAN OIL

RP- HPLC and Visible Spectrophotometric methods for the Estimation of Meropenem in Pure and Pharmaceutical Formulations

Hyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.

Journal of Chemical and Pharmaceutical Research, 2017, 9(9): Research Article

Asian Journal of Chemistry Vol. 21, No. 1 (2009),

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

Converting a CHP Method for Insulin to Agilent Poroshell 120 Columns

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method

Compliance. Minor editorial changes have been made to update the monograph to the current USP style.

Development and validation of stability indicating RP-LC method for estimation of calcium dobesilate in pharmaceutical formulations

Revision of monograph in the 4 th Edition of The International Pharmacopoeia (August 2008)

Development and Validation of a Simultaneous HPLC Method for Quantification of Amlodipine Besylate and Metoprolol Tartrate in Tablets

USP Method Transfer of Ziprasidone HCl from HPLC to UPLC

Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

Comparison of conventional HPLC with UPLC method for determination of albuterol sulfate and it s impurities in pharmaceutical formulation

DRAFT UGANDA STANDARD

Analysis of Isoflavones with the PerkinElmer Flexar FX-15 UHPLC System Equipped with a PDA Detector

Available online Research Article

Analysis of Commercially Available Products Containing Stevia

Transcription:

Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016 Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica This monograph was also published in: Compendium of Food Additive Specifications. Joint FAO/WHO Expert Committee on Food Additives (JECFA), 82 nd meeting 2016. FAO JECFA Monographs 19

1 of 6 REBAUDIOSIDE A FROM MULTIPLE GENE DONORS EXPRESSED IN YARROWIA LIPOLYTICA SYNONYMS New Specifications prepared at the 82 nd JECFA (2016) and published in FAO JECFA Monograph 19 (2016). ADI for steviol glycosides of 0-4 mg/kg bw (expressed as steviol) was established at the 69th JECFA (2008). DEFINITION Rebaudioside A is a steviol glycoside composed predominantly of rebaudioside A with minor amounts of other steviol glycosides such as rebaudioside B, rebaudioside D, rebaudioside M, and stevioside. Rebaudioside A is obtained from the fermentation of a non-toxigenic non-pathogenic strain of Yarrowia lipolytica that is genetically modified with heterologous genes from multiple donor organisms to overexpress steviol glycosides. After removal of the biomass by solid-liquid separation and heat treatment, the process involves concentration of the steviol glycosides (e.g. by resin adsorption), followed by purification of the rebaudioside A by crystallization and drying. Ion exchange resins may be used in the purification process. The final product may be spray-dried. Chemical names 13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-Dglucopyranosyl)oxy]kaur-16-en-18-oic acid, β-d-glucopyranosyl ester C.A.S. number 58543-16-1 Chemical formula C 44H 70O 23 Structural Formula 1 Formula weight 967.01 1 FCC10-: U.S. Pharmacopeial Convention, Rebaudioside A Monograph, 2016. Reproduced with permission.

2 of 6 Assay DESCRIPTION Not less than 95% calculated on the anhydrous basis White to light yellow powder, odourless or having a slight characteristic odour. About 200-300 times sweeter than sucrose. FUNCTIONAL USES Sweetener CHARACTERISTICS IDENTIFICATION 2 Solubility (Vol. 4) HPLC ph (Vol. 4) Infrared spectrum PURITY Related Steviol Glycosides Freely soluble in ethanol:water 50/50 (v/v), sparingly soluble in water, and sparingly soluble in ethanol. The main peak in the Sample chromatogram obtained by following the procedure in METHOD OF ASSAY corresponds to rebaudioside A. Between 4.5 and 7.0 (1 in 100 solution) The infrared spectrum of the sample using attenuated total reflectance (ATR) analysis corresponds to that of the standard. Rebaudioside A standards available from Wako Pure Chemical Industries, Ltd. Japan, US Pharmacopeia, USA, and ChromaDex, USA The sum of the percentages for stevioside, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside F, dulcoside A, rubusoside and steviolbioside is NMT 5% on the anhydrous basis. See description under TESTS. Total ash (Vol. 4) Not more than 1% Water (Vol. 4) 4 Not more than 6% Determination using the Karl Fischer Titrimetric Method. Residual solvents (Vol. 4) Arsenic (Vol. 4) Lead (Vol. 4) Not more than 200 mg/kg methanol and not more than 5000 mg/kg ethanol (Method I in Vol. 4, General Methods, Organic Components, Residual Solvents) Not more than 1 mg/kg Determine using a method appropriate to the specified level. The selection of sample size and method of sample preparation may be based on the principles of the methods described in Vol. 4 (under General Methods, Metallic Impurities ). Not more than 1 mg/kg Determine using a method appropriate to the specified level. The selection of sample size and method of sample preparation may be based on the principles of the methods described in Vol. 4 (under General Methods, Metallic Impurities ). 2 FCC10-: U.S. Pharmacopeial Convention, Rebaudioside A Monograph, 2016. Reproduced with permission.

3 of 6 TESTS PURITY Related steviol glycosides Solution A, Solution B, Mobile phase, Diluent, System suitability solution, Sample, Sample solution, Standard solution 2, HPLC conditions, and System suitability: Prepare as directed in METHOD OF ASSAY. Analysis Separately inject equal volumes of the System suitability solution, Standard solution 2, and Sample solution into the chromatograph. Calculate the percentages of rebaudioside D, stevioside, rebaudioside F, rebaudioside C, dulcoside A, rubusoside, rebaudioside B, and steviolbioside in the portion of the sample taken as follows, which takes into account the UV response factors between the analytes and rebaudioside A: Result = (r U/r S) (C S/C U) (1/F) 100 r U = peak area for the analyte in the Sample solution r S = peak area for rebaudioside A in Standard solution C S = concentration of rebaudioside A in Standard solution 2, corrected for purity and water content (mg/ml) C U = concentration of the sample in the Sample solution corrected for water content (mg/ml) F = relative response factor (see Table 2) Add together the individual percentages of the eight measured steviol glycoside impurities corrected for water. METHOD OF ASSAY 3 Determine the percentages of the individual steviol glycosides by HPLC (Vol. 4) under the following conditions. Mobile phase Solution A: 5 mm potassium phosphate buffer, ph 3.0. Prepare by dissolving 1.36 g of potassium dihydrogen phosphate (KH 2PO 4) in water in a 2-L volumetric flask, adjusting with phosphoric acid to a ph of 3.0, diluting to volume with water, and passing through a 0.45-µm filter. Solution B: Acetonitrile Diluent Solution A and Solution B (65:35 v/v) Standard solution 1 1.2 mg/ml of rebaudioside A in Diluent. Prepare by dissolving in 80% volume of Diluent, sonicating until dissolved (2 5 min), and diluting to volume. High purity rebaudioside A standards available from Wako Pure Chemical Industries, Ltd. Japan, US Pharmacopeia, USA, and ChromaDex, USA. 3 FCC10-: U.S. Pharmacopeial Convention, Rebaudioside A Monograph, 2016. reproduced with permission.

4 of 6 Standard solution 2 0.03 mg/ml of rebaudioside A in Diluent. Prepare by dissolving in 80% volume of Diluent, sonicating until dissolved (2 5 min), and diluting to volume. System suitability solution Prepare a solution containing all nine named steviol glycosides for peak identification and system suitability as follows. 1.2 mg/ml of USP Steviol Glycosides System Suitability RS (available from US Pharmacopeia, USA) in Diluent. Prepare by dissolving in 80% volume of Diluent, sonicating until dissolved (2 5 min), and diluting to volume. Alternative preparation: Prepare a solution for peak identification and system suitability containing 0.6 mg/ml each of rebaudioside D, rebaudioside A, stevioside, rebaudioside F, rebaudioside C, dulcoside A, rubusoside, rebaudioside B, and steviolbioside in Diluent (standards available from Wako Pure Chemical Industries, Ltd. Japan, US Pharmacopeia, USA, and ChromaDex, USA). Sample Rebaudioside A is hygroscopic, and accurate quantitative analysis requires moisture equilibration before analysis. Equilibrate sample specimens in the lab no less than 24 h before weighing by spreading into a thin layer no more than 1/4 in. Intermittent stirring will ensure uniform moisture absorption. The water content of the equilibrated samples should be determined at the time of weighing using Water Determination (Karl Fischer Titrimetric Method) (Vol. 4) Sample solution 1.2 mg/ml of the Sample in Diluent. Prepare by dissolving in 80% volume of Diluent, sonicating until dissolved (2 5 min), and diluting to volume. HPLC Conditions Detector: UV 210 nm Column: 25-cm 4.6-mm, packed with 5-µm reversed phase C18 silica stationary phase (YMC-Pack ODS-AQ, YMC America Inc.), or equivalent Column temperature: 32 Flow rate: 0.5 ml/min Injection volume: 15 µl Gradient program: See Table 1 Table 1 Time (min) Solution A (%) 0 90 10 10 65 35 25 65 35 35 25 75 50 25 75 52 90 10 67 90 10 Solution B (%)

5 of 6 System suitability Sample: System suitability solution Suitability requirements Suitability requirement 1: The relative standard deviation of the rubusoside peak area is no more than 2.5% for five replicate injections. Suitability requirement 2: The resolution, R, between rebaudioside A and stevioside is no less than 1.7. Suitability requirement 3: The relative standard deviation of the rebaudioside A peak area is no more than 1.5% for five replicate injections. Analysis Separately inject equal volumes of the System suitability solution, Standard solution 1, and Sample solution into the chromatograph. Use the chromatogram of the Standard solution to identify the rebaudioside A peak, and the chromatogram of the System suitability solution to identify the peaks corresponding to the other eight steviol glycosides listed in Table 2. Table 2: Chromatographic Profile Compound Relative Retention Time Rebaudioside D 0.80 0.83 Rebaudioside A 1.00 1.00 Stevioside 1.03 1.22 Rebaudioside F 1.10 1.02 Rebaudioside C 1.15 0.98 Dulcoside A 1.21 1.16 Rubusoside 1.44 1.06 Rebaudioside B 1.59 1.07 Steviolbioside 1.61 1.38 Relative Response Factor Calculate the percentage of rebaudioside A in the portion of the sample taken: Result = (r U/r S) (C S/C U) 100 r U = peak area for the analyte in the Sample solution r S = peak area for rebaudioside A in Standard solution 1 C S = concentration of rebaudioside A in Standard solution 1, corrected for purity andwater content (mg/ml)

6 of 6 C U = concentration of the sample in the Sample solution corrected for water content (mg/ml) Figure. Chromatogram of System suitability solution Conditions: 1.2 mg/ml USP Steviol Glycosides System Suitability RS